Secnidazole - Lupin

Drug Profile

Secnidazole - Lupin

Alternative Names: Solosec; SYM-1219

Latest Information Update: 16 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Symbiomix Therapeutics
  • Class Antibacterials; Antiprotozoals; Nitroimidazoles; Small molecules
  • Mechanism of Action DNA synthesis inhibitors; Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Bacterial vaginosis

Most Recent Events

  • 11 Oct 2017 Symbiomix Therapeutics has been acquired by Lupin
  • 11 Oct 2017 Symbiomix Therapeutics and Lupin expect to launch secnidazole for Bacterial vaginosis in mid-2018
  • 18 Sep 2017 Registered for Bacterial vaginosis in USA (PO) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top